MET and metastatic colorectal cancer: For example, in MET-amplified tumor models, antibodies that bind to nonoverlapping epitopes of receptor tyrosine kinase MET enhanced antagonistic activity [34], while a combination of two anti-EGFR antibodies addressing disparate epitopes helped circumvent cetuximab resistance in metastatic colorectal cancer models [35].